|
ARNI联合他汀对老年高血压并HFpEF患者疗效的观察
|
Abstract:
目的:探讨ARNI联合他汀对老年高血压并HFpEF患者的临床疗效。方法:选择2020年1月~2021年10月青大附院住院的年龄 ≥ 65岁高血压合并射血分数保留的心力衰竭患者,根据用药方案分为ARNI + 他汀组40例,他汀组40例,对照组40例,分析治疗前、治疗6个月后的临床疗效,实验室指标:C反应蛋白(CRP)、低密度脂蛋白(LDL)、N端前体脑利钠肽(NT-proBNP),心脏超声指标:左心房容积指数(LAVI)、左心室质量指数(LVMI)、左心室舒张早期二尖瓣血流最大速度/舒张早期二尖瓣环峰值速度(E/e’)、左心室射血分数(LVEF)、不良反应、再住院及死亡事件,评估ARNI联合他汀对老年高血压并HFpEF患者生活质量、心功能及预后的影响。结果:治疗后,ARNI + 他汀组:总有效率提高,脉压、LDL、CRP、NT-proBNP、LAVI、LVMI、E/e’水平明显降低(p < 0.05),他汀组:脉压、LDL、CRP、NT-proBNP、LVMI、E/e’下降(p < 0.05),对照组:脉压下降(p < 0.05),其他指标差异无统计学意义(p > 0.05);组间比较:ARNI + 他汀组比另外两组,脉压、LDL、CRP、NT-proBNP、LAVI、LVMI、E/e’水平明显降低(p < 0.05);各组随访6个月因心衰再入院患者分别为2例(5%),5例(12.5%),10例(25%),对照组死亡1例。各组无明显药物不良反应,差异无统计学意义(p > 0.05)。结论:ARNI联合他汀可以明显改善老年高血压并HFpEF患者生活质量、逆转心肌重塑、改善心脏功能及预后,可以指导临床用药。
Objective: To investigate the clinical efficacy of ARNI combined with statins in elderly patients with hypertension complicated with HFpEF. Methods: From January 2020 to October 2021, hypertensive heart failure patients aged ≥ 65 years with retained ejection fraction were selected and divided into ARNI + statin group (n = 40), statin group (n = 40) and control group (n = 40) according to medica-tion regimen. The clinical efficacy before and after 6 months of treatment were analyzed, laboratory indicators: C-reactive protein (CRP), low-density lipoprotein (LDL), N-terminal precursor brain na-triuretic peptide (NT-proBNP), cardiac ultrasound indicators: Left atrial volume index (LAVI), left ventricular mass index (LVMI), left ventricular early diastolic maximum mitral flow velocity/early diastolic mitral annular peak velocity (E/e’), left ventricular ejection fraction (LVEF), adverse drug reactions, rehospitalization and death endpoints, and evaluate the effect of ARNI combined with statin on the quality of life, cardiac function and prognosis of elderly patients with hypertension and HFpEF. Results: After treatment: the ARNI + statin group increased the total effective rate, and sig-nificantly decreased the levels of pulse pressure, LDL, CRP, NT-proBNP, LAVI, LVMI, and E/e’ (p < 0.05). Pulse pressure, LDL, CRP, NT-proBNP, LVMI, E/e’ decreased in the statin group (p < 0.05). The pulse pressure in the control group decreased (p < 0.05), and there was no significant difference in other indicators (p > 0.05); Comparison between groups: compared with the other two groups, the ARNI + statin group had significantly lower pulse pressure, LDL, CRP, NT-proBNP, LAVI, LVMI, and E/e’ levels (p < 0.05); During the 6-month follow-up in each group, 2 patients (5%), 5 patients (12.5%), and 10 patients (25%) were readmitted due to
[1] | 廖玉华, 杨杰孚, 张健, 等. 舒张性心力衰竭诊断和治疗专家共识[J]. 临床心血管病杂志, 2020, 36(1): 1-10.
https://doi.org/10.13201/j.issn.1001-1439.2020.01.001 |
[2] | Solomon, S.D., McMurray, J.J.V., Anand, I.S., et al. (2019) Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. The New England Journal of Medicine, 381, 1609-1620.
https://doi.org/10.1056/NEJMoa1908655 |
[3] | Ge, J. (2020) Coding Proposal on Phenotyping Heart Failure with Preserved Ejection Fraction: A Practical Tool for Facilitating Etiology-Oriented Therapy. Cardiology Journal, 27, 97-98. https://doi.org/10.5603/CJ.2020.0023 |
[4] | 中国心衰中心联盟. 舒张性心力衰竭早期防治专家建议[J]. 临床心血管病杂志, 2021, 37(1): 1-6. |
[5] | van Heerebeek, L., Hamdani, N., Falc?o-Pires, I., et al. (2012) Low Myocardial Protein Kinase G Activity in Heart Failure with Preserved Ejection Fraction. Circulation, 126, 830-839.
https://doi.org/10.1161/CIRCULATIONAHA.111.076075 |
[6] | 赵楠楠, 刘颖萍, 王志男, 等. 他汀类药物对慢性心力衰竭的疗效[J]. 武警医学, 2015, 26(6): 606-608. |
[7] | Unger, T., Borghi, C., Charchar, F., et al. (2020) In-ternational Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75, 1334-1357. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026 |
[8] | 丘伟达, 黎励文. 2019 ESC心力衰竭协会射血分数保留心力衰竭诊断共识建议解读[J]. 中国循环杂志, 2019, 34(z1): 72-75. |
[9] | 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志, 2018, 46(10): 760-789.
https://doi.org/10.3760/cma.j.issn.0253-3758.2018.10.004 |
[10] | 刘诚, 李江华, 李唐志铭, 等. 葛式分型应用在射血分数保留型心力衰竭的流行病学调查[J]. 中国心血管病研究, 2021, 19(6): 481-488. |
[11] | Tokitsu, T., Yama-moto, E., Hirata, Y., et al. (2015) Clinical Significance of Pulse Pressure in Patients with Coronary Artery Disease. In-ternational Journal of Cardiology, 190, 299-301. https://doi.org/10.1016/j.ijcard.2015.04.101 |
[12] | Kong, Q. and Blanton, R.M. (2013) Protein Kinase G I and Heart Failure: Shifting Focus from Vascular Unloading to Direct Myocar-dial Antiremodeling Effects. Circulation: Heart Failure, 6, 1268-1283.
https://doi.org/10.1161/CIRCHEARTFAILURE.113.000575 |
[13] | 廖玉华, 余淼, 史河水. 心外膜脂肪组织: 心血管病防治的新靶点[J]. 临床心血管病杂志, 2020, 36(1): 11-14. |
[14] | Solomon, S.D., Zile, M., Pieske, B., et al. (2012) The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase 2 Double-Blind Randomised Controlled Trial. The Lancet, 380, 1387-1395. https://doi.org/10.1016/S0140-6736(12)61227-6 |
[15] | Januzzi Jr., J.L., Prescott, M.F., Butler, J., et al. (2019) As-sociation of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment with Cardiac Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction. Journal of the Amer-ican Medical Association, 322, 1085-1095.
https://doi.org/10.1001/jama.2019.12821 |
[16] | Desai, A.S., Solomon, S.D., Shah, A.M., et al. (2019) Effect of Sacubitril-Valsartanvs Enalapril on Aortic Stiffness in Patients with Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Journal of the American Medical Association, 322, 1077-1084. https://doi.org/10.1001/jama.2019.12843 |
[17] | 俞旭波, 洪浪, 李林峰. 阿托伐他汀联合美托洛尔治疗慢性心力衰竭[J]. 实用临床医学, 2015, 16(11): 3-6. |